glp-1 cardiovascular outcomes trial august 2025 Pipeline Update: - Prime Therapeutics Cardiovascular outcome studies with GLP-1

The reductions noted in this trial, the team noted, were associated with long-term reductions in alcohol-related negative consequences, improvement in mental health, and aligns with improvement in self-evaluated general and psychological health in the semaglutide group in the trial, although these improvements were modest. The most common adverse effects reported were gastrointestinal, and were more frequent in the semaglutide group, but most were short-lived, and none were severe

Most people will regain weight, said Neal

Stimulation of GLP-1 receptor inhibits methylglyoxal-induced mitochondrial dysfunctions in H9c2 cardiomyoblasts: potential role of Epac/PI3K/Akt pathway

Some people notice a subtle dryness that comes and goes

Keeping a simple hydration log or using smartphone reminders can help patients track intake and identify patterns before dehydration becomes clinically significant

Certain medical conditions and histories can make this type of medication a poor fit, which is why a proper medical review is always required before starting